Publications

Allen BC, Vincent MJ, Lipworth L, Panko JM, Suh M, Jiang X, Mumma MT, Proctor DM. 2025. Lung cancer risk assessment associated with exposure to hexavalent chromium: Results of pooled analysis of three cohorts. J Occup Environ Hyg 22(10):821-835; doi: 10.1080/15459624.2025.2502491.  PMID: 40435461.

Preib MT, Emden MR, Sacks NC, Mitrani-Gold FS, Ju S, Kawano Y, Kawamatsu S, Joshi AV. 2025. Prevalence and economic evaluation of acute uncomplicated cystitis in women from Japan: A retrospective cohort study. JAC Antimicrob Resist 7(5):dlaf178; doi: 10.1093/jacamr/dlaf178. PMID: 41113066.

Nordyke RJ, Patterson JA, Motyka J, March B, Kirson NY, Long G. 2025. The impact of the Inflation Reduction Act’s drug price negotiation program on incentives for clinical development of new drugs. Value Health; doi: 10.1016/j.jval.2025.08.011. Online ahead of print Sept. 1, 2025. PMID: 40902797.

Proctor D, Jiang X, Reichert H, Thompson C. 2025. Why rat oral cavity tumors should not be the basis of quantitative cancer risk assessment for oral exposure to hexavalent chromium. Toxicol Sci kfaf112; doi: 10.1093/toxsci/kfaf112. Online ahead of print August 8, 2025. PMID: 40795394.

Clouser MC, Suh M, Movva N, Hildebrand JS, Pastula ST, Schoehl M, Hindoyan A, Balasubramanian A, et al. 2025. A systematic literature review of MTAP deletions in solid and hematologic cancers. Cancer Treat Res Comm 44:100966; doi: 10.1016/j.ctarc.2025.100966. PMID: 40729867.

Duong T, Haselkorn T, Miller B, Coats J, Jensen I, Ward E, Wood M, Graham RJ, Servais L. 2025. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis 20(1):224. doi: 10.1186/s13023-025-03583-w.

Nordyke RJ, Motyka J, Patterson JA. 2025. The association of 340B program drug margins with covered entity characteristics. Inquiry 62(Jan-Dec):469580251324051; doi: 10.1177/00469580251234051. PMID: 4012322.

Wikoff DS, Vincent MJ, Heintz MM, Pastula ST, Reichert H, Klaren WD, Haws LC. 2025. Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: A case study examining associations between PFOA and PFOS exposures and vaccine response. Toxicol Sci 204(1):96-115; doi: 10.1093/toxsci/kfae152. PMID: 39792025.

Pastula ST, Bylsma LC, Rege SV, Lewis RJ, Movva N. 2025. Scoping review of indices to measure a community’s health status. Popul Health Manag 28(1):37-49; doi: 10.1089/pop.2024.0138. PMID: 39558762.

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002. PMID: 39357669.